Asahi shares mark weekly slide after cyberattack halts production
LONDON - Avacta Group plc (AIM:AVCT) will release its unaudited interim results for the six months ended June 30, 2025, on September 30, 2025, according to a company statement issued Monday.
The oncology drug developer will host a live investor presentation on the same day at 14:00 BST via Investor Meet Company, featuring Chief Executive Officer Christina Coughlin and Chief Financial Officer Brian Hahn.
The company also announced a scheduling change for its presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The abstract titled "A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors" will now be presented on October 19 at 12:00-12:45 in Hall 25. Dr. William D. Tap will deliver the presentation, which has been assigned abstract number 964P in the Developmental Therapeutics session.
Avacta, which describes itself as a life sciences company developing targeted oncology drugs, trades on London’s AIM market. The company stated that the results presentation will be made available on its website following the investor call.
The announcement was made through a regulatory press release issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.